Musa Jonah, Kocherginsky Masha, Magaji Francis A, Maryam Ali J, Asufi Joyce, Nenrot Danjuma, Burdett Kirsten, Katam Neelima, Christian Elizabeth N, Palanisamy Nisha, Odukoya Olukemi, Silas Olugbenga A, Abdulkareem Fatimah, Akpa Philip, Badmos Kabir, Imade Godwin E, Akanmu Alani S, Gursel Demirkan B, Zheng Yinan, Joyce Brian T, Achenbach Chad J, Sagay Atiene S, Anorlu Rose, Wei Jian-Jun, Ogunsola Folasade, Murphy Robert L, Hou Lifang, Simon Melissa A
Department of Obstetrics and Gynecology, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria.
Department of Preventive Medicine, Division of Cancer Epidemiology and Prevention, Feinberg School of Medicine, Northwestern University, Chicago, USA.
Infect Agent Cancer. 2023 Nov 1;18(1):68. doi: 10.1186/s13027-023-00550-7.
Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria.
We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America's National Institutes of Health/National Cancer Institute funded project titled 'Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria'. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test.
A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC +), and 47 (19.7%) were HIV-positive (HIV +/ICC +). The HIV +/ICC + patients were younger with median age 46 (IQR: 40-51) years compared to 57 (IQR: 45-66) among HIV-/ICC + (P < 0.001). Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV +/ICC + diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC +. The HIV-/ICC + women had better OS compared to HIV +/ICC + participants (p = 0.018), with 12-month OS 84.1% (95%CI 75-90%) and 67.6% (95%CI 42-84%) respectively.
ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival.
浸润性宫颈癌(ICC)是一种与艾滋病病毒(HIV)相关的癌症,是可预防的,通过筛查可检测到包括早期ICC阶段在内的癌前阶段,从而提供治疗和治愈的机会。HIV感染女性中ICC的高发病率以及就诊时往往处于ICC晚期且治疗设施有限,常常导致早期死亡。我们旨在比较尼日利亚ICC患者的流行病学特征以及HIV状态下的生存差异。
2018年3月至2022年9月期间,我们在尼日利亚乔斯大学教学医院和拉各斯大学教学医院的两个联邦学术医院研究点进行了一项队列研究。我们纳入了经组织学确诊且HIV状态已知、国际妇产科联盟(FIGO)分期明确的ICC女性患者,该研究是美国国立卫生研究院/国家癌症研究所资助项目“尼日利亚HIV相关癌症的表观基因组生物标志物”的一部分。主要结局是全因死亡率,评估总体生存率(OS)以及ICC诊断后的死亡时间。使用Kaplan-Meier方法估计OS分布,并使用对数秩检验在组间进行比较。
共有239名确诊ICC的女性被纳入本分析,其中192名(80.3%)为HIV阴性(HIV-/ICC+),47名(19.7%)为HIV阳性(HIV+/ICC+)。HIV+/ICC+患者更年轻,中位年龄为46岁(四分位间距:40 - 51岁),而HIV-/ICC+患者为57岁(四分位间距:45 - 66岁)(P < 0.001)。鳞状细胞癌是80.4%的ICC诊断中最常见的组织病理学类型,两组中68.1%为中度分化肿瘤分级。HIV+/ICC+诊断处于FIGO晚期的比例为64.9%,而HIV-/ICC+为47.9%。与HIV+/ICC+参与者相比,HIV-/ICC+女性的OS更好(p = 0.018),12个月OS分别为84.1%(95%置信区间75 - 90%)和67.6%(95%置信区间42 - 84%)。
HIV感染女性中ICC的诊断年龄相对较轻,与未感染HIV的女性相比,总体生存概率显著更低。HIV感染女性就诊和诊断处于晚期的趋势可能部分解释了总体生存的差异。